ClinicalTrials.gg
CompletedNCT03681548Updated Nov 20, 2019

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

A Phase 1 interventional study of Doxorubicin Hydrochloride Liposome Injection in Ovarian Cancer Recurrent, sponsored by Ayana Pharma Ltd.,. Completed at 15 sites in India. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Ayana Pharma Ltd., · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Enrollment
22nd of 42
52 · median 53
Started
2018
with 3 others
Phase 1
11 of 42
none open now
Registered
36th of 42
by date
Lead sponsor
1 of 42
Ayana Pharma Ltd.,

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 22nd largest by enrollment, is one of 4 that started in 2018, is one of 11 in phase 1, and was the 36th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .

Read the detailed description

This study is a randomized, open label, two arm, single dose, crossover bioequivalence study. This study will be conducted in female subjects aged 18 to 65 years diagnosed with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with Doxorubicin Hydrochloride Liposome Injection product. Each subject will be randomized to one of the two treatment sequences (RT or TR) according to a randomization scheme prepared prior to start of the trial. Serial blood samples for determination of free and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle., This study has an adaptive 2-stage design. A sufficient number of subjects with ovarian cancer shall be recruited to have approximately 42 evaluable subjects completing all follow up procedures (Stage 1). An interim analysis of free and encapsulated doxorubicin will be performed at the end of Stage 1. If the bioequivalence of encapsulated and free doxorubicin has been established, then the study will be stopped. Otherwise, the study may continue into Stage 2 with additional number of ovarian cancer subjects. A final evaluation of bioequivalence based on free and encapsulated doxorubicin will be performed at the end of Stage 2 and will include all enrolled subjects completing the study. Bioequivalence criteria: the 94.12% confidence interval of the ratio of geometric means of TEST to REFERENCE for Cmax, AUC0-t, AUC0-∞, for free and encapsulated doxorubicin should be between 80.00% and 125.00%.

03

Conditions studied

  • Ovarian Cancer Recurrent

Browse trials for

Keywords

  • liposomal doxorubicin injection
  • bioequivalence study
  • ovarian cancer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult female subjects between 18 to 65 years of age (both inclusive) at the time of screening visit.
  2. Subjects with histologically or cytological proven ovarian cancer, whose disease has progressed or recurred after platinum-based chemotherapy and scheduled to start therapy with or who are already receiving an approved dose of 50 mg per meter square Doxorubicin Hydrochloride Liposome Injection product.
  3. Subjects expected to be able to receive both doses of Doxorubicin Hydrochloride Liposome Injection.
  4. Subjects eligible for receiving a dose of 50 mg per meter square of Doxorubicin Hydrochloride Liposome Injection.
  5. Subjects with Performance less than or equal to 2 on the (ECOG) performance scale
  6. Cardiac function () greater than or equal to 50 percentage.
  7. Adequate renal, hepatic and bone marrow function without blood product or hematopoietic growth factor support.
  8. Subjects able to understand the nature of this study.
  9. Availability of subject for the entire study period and willingness to adhere to protocol requirements.
  10. For subjects of , serum beta HCG pregnancy test at screening and urine pregnancy test prior to dosing must be negative and subjects agree to use an acceptable and effective approved method of
  11. Subjects of non-childbearing potential who are either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or greater than 1 year with follicle stimulating hormone in the postmenopausal range
  12. Signed written .

Exclusion criteria

Exclusion Criteria:

  1. Subjects with history or presence of significant:

    • Allergy or significant history of or idiosyncratic reactions to a conventional formulation of Doxorubicin Hydrochloride and/or any components of Doxorubicin Hydrochloride liposome injection.
    • pulmonary, hepatic, renal, bone marrow, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
    • Impaired cardiac function
  2. Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within the past one year.
  3. Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, p. carinii or other microorganism (bacterial, viral or fungal).
  4. Clinically significant illness (except ovarian cancer) within four weeks prior to dosing.
  5. Prior radiation therapy to mediastinum
  6. Concomitant use of other cytotoxic or cytostatic drugs or of radiotherapy within four weeks prior to dosing
  7. Subject under treatment of myelotoxic drugs, other than doxorubicin (liposomal).
  8. Use of prescription or non-prescription herbal and dietary supplements, within 7 days prior to dosing.
  9. Subjects with other known active requiring treatment within 3 years (except for ovarian and/or skin cancer).
  10. Subjects with known and/or subjects considered for radiotherapy treatment.
  11. Positive result to any of the following: -1/2, hepatitis A, B and C; syphilis.
  12. Use of enzyme-modifying drugs in the previous 30 days prior to dosing and during the study
  13. Subjects who have:

    • Systolic blood pressure less than 90 mmHg or more than 160 mmHg
    • Diastolic blood pressure less than 60 mmHg or more than 95 mmHg
    • Pulse rate below 55 per min. or above 100 per min14.
  14. Subjects with abnormal laboratory parameters
  15. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other device or drug trial(s).
  16. Subjects who are legally detained in an official institute.
  17. Subjects with prior doxorubicin exposure that would result in a total lifetime exposure of 550 mg per meter square or more after four cycles of treatment.
  18. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments
  19. Females of unwilling to use acceptable (as identified in the protocol) throughout the trial and for 6 months after the last dose of study drug.
  20. Pregnant or breast-feeding subjects.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Reference Product - R

    Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).

    Drug: Doxorubicin Hydrochloride Liposome Injection

  • Experimental
    Test Product - T

    Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).

    Drug: Doxorubicin Hydrochloride Liposome Injection

Interventions

  • 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation

    Also known as: Doxorubicin Hydrochloride Liposomal injection 20 mg/10 mL

06

What researchers measure

Primary outcomes

  1. Assessment of bioequivalence using Cmax of encapsulated and free doxorubicin in plasma

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using maximum plasma doxorubicin concentration (Cmax) of encapsulated and free doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

  2. Assessment of bioequivalence using AUC (0-t) of encapsulated and free doxorubicin in plasma

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation (AUC 0-t) of encapsulated and free doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

  3. Assessment of bioequivalence using AUC (0-inf) of encapsulated and free doxorubicin in plasma

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using areas under the plasma concentration versus time curve calculated from 0 to infinity (AUC 0-inf) of encapsulated and free doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

Secondary outcomes

  1. Assessment of bioequivalence using Cmax of total doxorubicin in plasma

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using Cmax of total doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

  2. Assessment of bioequivalence using AUC (0-t) of total doxorubicin in plasma

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using AUC (0-t) of total doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

  3. Assessment of bioequivalence using AUC (0-inf) total doxorubicin as secondary analyte

    Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using AUC (0-inf) of total doxorubicin measurements in plasma.

    Time frame: Throughout 15 days after both dosing.

  4. Assessment of safety

    Assessment of incidence of adverse events

    Time frame: Troughout 42 days after first dosing

07

Study locations

15 sites
  • MNJ Institute of Oncology & Regional Cancer Center
    Hyderabad, Andhra Pradesh 500004, India
  • HCG City Cancer Centre
    Vijayawada, Andhra Pradesh 520002, India
  • Mahatma Gandhi Cancer Hospital & Research Institute
    Visakhapatnam, Andhra Pradesh 530017, India
  • Nirmal Hospital Pvt. Ltd.
    Surat, Gujarat 395002, India
  • Unique Hospital - Multispeciality and Research Institute
    Sūrat, Gujarat 395002, India
  • Aman Hospital and Research Center
    Vadodara, Gujarat 390021, India
  • Kailash Cancer Hospital And Research Center
    Vadodara, Gujarat 391760, India
  • K R Hospital
    Mysore, Karnataka 570001, India
  • Apex Wellness Rishikesh Hospital
    Nashik, Maharashtra 422 002, India
  • HCG Manavata Cancer Centre
    Nashik, Maharashtra 422002, India
  • Noble Hospital Pvt Ltd.
    Pune, Maharashtra 411013, India
  • Sparsh Hospitals & Critical Care (P) Ltd.
    Bhubaneshwar, Odisha 751007, India
  • Sri Ramachandra Medical Centre
    Chennai, Tamil Nadu 600116, India
  • Saveetha Medical College & Hospital
    Chennai, Tamil Nadu 602105, India
  • VGM Hospital
    Coimbatore, Tamil Nadu 641005, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2019, 5 months.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 5 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 24, 2018
StartActual
Aug 29, 2018
Primary completionActual
Feb 8, 2019
CompletionActual
Mar 7, 2019
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03681548
Lead sponsor
Ayana Pharma Ltd.,
Collaborators
Lambda Therapeutic Research Ltd.
Responsible party
Sponsor
First posted
Sep 24, 2018
Start date
Aug 29, 2018
Primary completion
Feb 8, 2019
Completion
Mar 7, 2019
Last update
Nov 20, 2019

Study contacts

Rakesh J Patel, MD Pharm
study director · Lambda Therapeutic Research Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion